Next Live Webinars
Continuous manufacturing: excipient characterization and formulation development

Continuous manufacturing: excipient characterization and formulation development
MORE INFORMATION & REGISTRATION
Presentation: Development and Implementation of a Continuous Manufacturing Process for a Complex Modified Release Formulation
Key Learnings:
- In less than six months, a modified-release formulation and process were developed for clinical supply using continuous direct compression.
- NIR and RTD models were developed as part of the control strategy to ensure content uniformity of both the API and the release-controlling polymer.
- A dissolution model was calibrated in the laboratory and successfully implemented at scale to monitor dissolution in real time.
Presentation: Rheological powder characterization of excipients to understand their behaving during feeding
Key Learnings:
- Understand how powder flowability can be characterized by rheological analysis
- Translate the results into predicting powder flowability into feeders within a case study
Date & Time & Timezone: Mar 12, 2026 05:00 PM CET Amsterdam, Berlin, Rome, Stockholm, Vienna
Speaker:

Dr. Vanessa Havenith
Technical Sales Manager, SE Tylose GmbH & Co. KG
Dr. Vanessa Havenith studied and obtained her doctorate in mineralogy at RWTH Aachen University. After completing her studies, she worked as Technical Sales Manager for SE Tylose GmbH & Co. KG in the field of industrial applications (building materials, petroleum and paints) from 2012 to 2021. In 2021, she moved to the pharmaceutical sector, where she is responsible for various key accounts within Europe as Technical Sales Manager.

Ricardo Sousa
Senior formulation development scientist, Hovione
Ricardo Sousa has a background in Biological Engineering and over 12 years of experience in pharmaceutical development, which contributes to a solid understanding of pharmaceutical sciences and technologies.
Throughout his career, he has developed technical expertise across spray drying, batch and continuous tableting, dry and wet granulation, and process analytical technologies. He is also skilled in modelling, data analysis, and statistical methods, supporting robust process understanding and optimization. In recent years, Ricardo has been mostly involved in continuous tableting, serving as the lead scientist for several projects conducted on the CDC‑10 line in Portugal
For more information & registration here:
Nitrites/Nitrosamines: The impacts on analytics, but not only

Nitrites/Nitrosamines: The impacts on analytics, but not only
Since 2018, nitrosamines have gone from an unexpected impurity issue to a persistent, industry-wide challenge. Detection limits have dropped, analytical complexity has increased and yet analytics alone rarely explain where the risk truly originates. In this expert talk, Daniel Nicolau and Philippe Tschopp step away from the usual webinar format to discuss what has really changed over the past years.
From nitrites in excipients and process influences to evolving expectations and growing development pressure, the conversation looks at why nitrosamine risk is now broader, harder to control, and more relevant than ever. This should be an interactive session, so we will be happy to receive questions and topics to discuss before and during the expert talk session.
Date & Time & Timezone: Mar 19, 2026 04:00 PM in Amsterdam, Berlin, Rome, Stockholm, Vienna
Speaker:
Daniel Nicolau is an Associate Principal Scientist at Reading Scientific Services Ltd (RSSL), serving as the technical lead for life science chromatography. Daniel has degrees in both Medicinal Chemistry and Chemical Biology, with a specialty in Mass Spectrometry.
Daniel created RSSL’s Extractables and Leachables (E&L), developing bespoke approaches that achieve the challenging scientific rigor while ensuring all testing exceeds regulatory guidelines.
Daniel also started the Nitrosamine impurity testing services, developing an abundance of analytical methods to meeting the ever-changing regulatory landscape and ever more demanding thresholds for an increasing list of nitrosamine species in an array of excipients and finished products.
Philippe Tschopp
Founder Pharma Excipients, Glatt Pharmaceutical Services; www.pharmaexcients.com
Philippe Tschopp has 25 years experience in the pharmaceutical industry. Both as a supplier of pharmaceutical excipients and in the CDMO business development for oral solid dosage from development at Glatt Pharmaceutical Services.
Covering projects in the field of multiparticulates, solubility enhancement, pediatrics and geriatrics, etc. with a strong interest in excipients, new drug delivery technologies and processes.
Philippe has founded www.pharmaexcipients.com
For more information & registration here:
Recorded Webinars:
Smarter Stabilization for Lipid Nanoparticles: Formulating Biopharmaceuticals with Sucrose
Optimizing Pharmaceutical Formulations: Strategies for Improving Stability and Minimizing Impurities
Rational Selection of Cyclodextrins for the Solubilization of Poorly Soluble Oral Drugs

















































































Addressing Raw Material Handling Challenges by Dry Granulation






Multiparticulates for paediatric oral drug delivery













